AstraZeneca Trial Shows Cancer Drug Survival Gains
The Phase III trial demonstrates significant survival benefits in patients with advanced gastric and gastroesophageal cancers.
Updated on Oct. 25, 2026 in Cancer
Live Poll
Do you believe current pharmaceutical investments in targeted cancer therapies are successfully extending patient survival?
AstraZeneca presented Phase III trial results showing that the drug sonesitatug vedotin reduced the risk of death by 53% in patients with gastric and gastroesophageal cancers. The study of 594 patients met its primary endpoint for overall survival in third-line and later treatment settings.
Why it matters
This trial offers a potential new treatment path for patients who have exhausted standard therapies and suffer from specific tumor expressions. The drug represents a significant investment for the company with projected peak sales reaching up to $5 billion.
The CLARITY-Gastric01 trial of 594 patients recorded a median survival of 10 months for those on sonesitatug vedotin compared to 5 months for standard treatments in third-line settings. Participants with tumor CLDN18.2 expression of 75% or higher saw a 41% lower risk of death.
The players
AstraZeneca
This global pharmaceutical company develops and commercializes innovative medicines for oncology, cardiovascular, and respiratory diseases.
KYM Biosciences
This biotechnology firm specializes in the development of targeted therapies and licensed its drug technology to AstraZeneca.
The details
Patients in the second-line and later population treated with the drug lived a median of 10.6 months, compared to 6.4 months for those receiving standard care. Researchers tested the drug across a range of CLDN18.2 tumor expression levels, including those as low as 25%.
Timeline
2023: AstraZeneca licensed the drug from KYM Biosciences.
July 2026: CLARITY-Gastric01 trial results were toplined.
October 25, 2026: Detailed Phase III results presented at ESMO congress.
The Big Picture
This development follows the rigorous clinical testing protocols established in the CLARITY-Gastric02 trial. The current findings shift the trajectory of gastroesophageal cancer treatment by validating the efficacy of targeted CLDN18.2 protein therapies.
This drug provides a new, potentially life-extending therapeutic option for patients with advanced gastric cancers who have failed previous treatments. The trial results specifically benefit patients based on their CLDN18.2 tumor expression levels.
The takeaway
The successful trial underscores the importance of biomarker testing in determining patient eligibility for targeted cancer treatments. Patients should consult with oncologists to determine if their specific tumor expression makes them candidates for such experimental therapies.
Further reading
For more information on clinical advancements, visit the Cancer section.
Live Poll
Do you believe current pharmaceutical investments in targeted cancer therapies are successfully extending patient survival?
